Login to Your Account



India’s drug IP record lands it at the top of PhRMA’s hit list

By Mari Serebrov
Regulatory Editor

Wednesday, March 12, 2014

Fearing that India’s lax attitudes toward drug patents might spread to other developing countries, U.S. drugmakers want the U.S. Trade Representative (USTR) to make an example of the country by once again branding it the worst of the worst in not honoring intellectual property (IP) rights.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription